Home
overview

  

 

SMi's 3rd annual Stem Cells conference will explore the latest scientific advances and business opportunities offered by stem cell research. There will be a variety of presentations from leading academics working in regenerative medicine and cell biology as well as industry professionals specialising in the transferral of stem cell research from preclinical to clinical development. Don't miss your chance to network with the leaders in this field, and look towards the future of this rapidly expanding area of medicine.

Prior to the conference, there will be a specialised  workshop on Practical Steps and Strategies for Obtaining Patent Protection of Stem Cells. This interactive half-day event will provide practical tips on drafting, filing and prosecution strategy for stem cell patent applications in order to provide flexibility and maximise protection. There will also be opportunities to learn how to deal with patent office objections and explore associated ethical and moral issues.

 


 View the conference programme

 Register for the event

 Download the brochure

 


 

"A very good conference with high quality speakers and and relevant presentations" Stem Cells 2010 attendee 

 

 Key topics at this year's conference:

 

  • Translation of current research into clinical products
  • Mobilising stem cells for tissue regeneration
  • The international stem cell patent landscape
  • In vitro alternatives in developmental toxicity testing
  • Bioethics in stem cell research
  • Tissue engineering strategies
  • The value of regenerative medicine intellectual property

Pharmaceutical and biotech industry professionals working in the follwing specialties:

  • Stem cell research
  • Regenerative medicine
  • Tissue engineering
  • Cell biology
  • Molecular Biology
  • Translational Medicine
  • Medical affairs
  • Embryonic stem cells
  • Research and development
  • Regulatory affairs
  • Compliance
  • Pharmacovigilance

 


Previous attendees have included representatives from the following organisations:

  • GlaxoSmithKline
  • Baxter
  • Merck Sharp & Dohme
  • European Patent Office
  • Federal Institute for Risk Assessment
  • Finnish Red Cross Blood Service
  • Genzyme
  • Johnson & Johnson
  • MHRA
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche
  • The Wellcome Trust
  • Asterand 
  • Military Institute of Hygiene & Epidemiology
  • Cancer Research UK
  • MTA Hungarian Academy of Sciences
  • Centre for Advanced Biomedical Imaging
  • University of Connecticut Health Centre
  • The William Harvey Research Institute

 

Conference programme

8:30 Registration and coffee

9:00 Chairman's opening remarks

Julian Hitchcock

Julian Hitchcock, Director, East of England Stem Cell Network

9:10 Regenerative medicine: Translation of current research into clinical products

Julia Polak

Julia Polak, Founder and Former Head of The Tissue Engineering and Regenerative Medicine Centre, Imperial College London

  • Definition of regenerative medicine, of tissue engineering and of stem cell therapy
  • Cells and scaffolds used
  • Progress so far
  • Challenges and opportunities
  • 9:50 Prerequisites for successful exploitation of stem cell assays in predictive toxicology

    Frank Bonner

    Frank Bonner, Chief Executive, Stem Cells for Safer Medicines

  • Factors impacting upon the productivity of drug development
  • The need for improved cell based models in drug screening
  • Potential application of stem cell assays
  • Challenges and future developments
  • 10:30 Morning coffee

    11:00 Cancer stem cells and clonal evolution: Implications for therapy

    Malcolm Alison

    Malcolm Alison, Professor of Stem Cell Biology, The William Harvey Research Institute, Barts and The London School of Medicine & Dentistry

  • Finding cancer stem cells
  • Clonal evolution as a major obstacle to tumour erradication
  • Targets for therapy: Notch, Wnts, Hedgehog, ALDH, EMT, miRNA
  • 11:40 Regenerative pharmacology

    Sara Rankin

    Sara Rankin, Professor in Leukocyte and Stem Cell Biology, National Heart & Lung Institute, Imperial College

  • Mobilising stem cells for tissue regeneration
  • Therapies for the selective mobilisation of mesenchymal stem cells
  • Molecular mechanisms regulating stem cell mobilisation
  • 12:20 Networking lunch

    13:50 Challenges in the stem cell supply chain

    Cathy Hua Ye

    Cathy Hua Ye, Senior Research Fellow, Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford

  • Stem cell source
  • Stem cell culture
  • Stem cell preservation
  • Quality control
  • 14:30 Maximising the value of regenerative medicine intellectual property: New perspectives

    Julian Hitchcock

    Julian Hitchcock, Director, East of England Stem Cell Network

  • Critical obstacles to investment in regenerative medicine intellectual property
  • Peculiarities of the international stem cell patent landscape
  • Assessing traditional exploitation models
  • New models of exploitation
  • 15:10 Afternoon tea

    15:40 Improving cell therapy manufacturing by industry academic collaborative research

    David Williams

    David Williams, Professor of Healthcare Engineering, Loughborough University

  • Approaches to industry academic collaboration
  • Automated therapeutic quality stem cell expansion
  • Regenerative medicine value systems
  • Future opportunities
  • 16:20 Stem cell therapies: To the clinic through the clinic

    Michael Whitaker

    Michael Whitaker, Dean of Development, Institute for Cell and Molecular Biosciences Medical School, University of Newcastle upon Tyne

  • The challenge of developing safe and cost-effective stem cell therapies
  • How biotech business models are sorely stretched when applied to cellular therapies
  • Market models based on close clinician-company partnerships
  • Present and future market opportunities
  • 17:00 Chairman’s closing remarks and close of day one

    8:30 Re-registration and coffee

    9:00 Chairman's opening remarks

    Glyn Stacey

    Glyn Stacey, Director, U.K. Stem Cell Bank, Head of Cell Biology and Imaging, National Institute for Biological Standards and Control, UK

    9:10 Nonclinical safety considerations in the development of stem cells as medicinal products

    Michaela Sharpe

    Michaela Sharpe, Drug Safety R&D Regenerative Medicine Expert, Pfizer

  • Key safety considerations (tumorigenicity, biodistribution and immunogenicity)
  • Utility of disease models in pivotal safety studies
  • Regulatory expectations regarding the type and quality of data required to support progress into the clinic
  • 9:50 Comprehensive workflow solutions for cellular analysis and stem cell research

    John  McDonald

    John McDonald, Cellular Analysis Technical Specialist, Roche Diagnostics

  • Analysis of cellular processes
  • Molecular mechanisms of stem cell self-renewal and differentiation
  • Commercially available ways of monitoring stem cell differentiation
  • What's in the pipeline?
  • 10:30 Morning coffee

    11:00 Lessons learned from clinical bone marrow transplantation

    Mike Watts

    Mike Watts, Director of Cell Processing Facility, Wolfson Cellular Therapy Unit, UCLH

  • Early disasters and improvements
  • Recent disasters and improvements
  • Avoiding perils and pitfalls
  • 11:40 Induced pluripotent stem cell models of human obesity

    Marc Lalande

    Marc Lalande, Director, University of Connecticut Stem Cell Institute

  • Update recent advances and research in iPS cells
  • Derivation of iPS cells from patients with a human obesity syndrome
  • Quality control and neuronal differentiation of patient-specific iPS cells
  • Screen for novel drug targets by RNA sequence analysis of iPS cells and neurons
  • 12:20 Networking lunch

    13:50 Targeting cancer stem cells in leukaemia

    Dominique Bonnet

    Dominique Bonnet, Head of Haematopoietic Stem Cell Laboratory, Cancer Research UK

  • Identification of leukemic stem cells (LSC) in AML and their heterogeneity
  • Potential pathways for targeting LSC
  • Can we targets the LSC niche
  • 14:30 Human embryonic stem cell research: 13 years after

    Dusko Ilic

    Dusko Ilic, Senior Lecturer in Stem Cell Science, Kings College London

  • Hypes and hopes
  • Where are we today – current advances and issues
  • What to expect in the future – reality check
  • 15:10 Afternoon Tea

    15:40 Delivery of stem cell lines for clinical application

    Glyn Stacey

    Glyn Stacey, Director, U.K. Stem Cell Bank, Head of Cell Biology and Imaging, National Institute for Biological Standards and Control, UK

  • Supporting translational research with high quality research materials as a vital component in regenerative medicine programmes
  • Dealing with the grey scale of "quality" from donor to recipient
  • International coordination and its key role in delivering therapies
  • Importance of managing the potential effects of adverse outcomes ahead of time
  • 16:20 CombiCult™ – A robust technology platform for stem cell differentiation

    Yen Choo

    Yen Choo, Chief Executive Officer, Plasticell

  • The differentiation bottleneck
  • Benefits of HTS for discovery of protocols
  • Recent improvements in the CombiCult™ platform
  • Examples of new protocols to generate human hepatocytes
  • 17:00 Chairman’s closing remarks and close of conference

    +

    VENUE

    Crowne Plaza - The City

    19 New Bridge Road, London, United Kingdom

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Crowne Plaza - The City

    19 New Bridge Road
    London EC4V 6DB
    United Kingdom

    Crowne Plaza - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.